|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007097,
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0030705,
umls-concept:C0034897,
umls-concept:C0036525,
umls-concept:C0205390,
umls-concept:C0231174,
umls-concept:C0344211,
umls-concept:C0460004,
umls-concept:C1514162,
umls-concept:C1522484,
umls-concept:C1831978
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-4-5
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
No treatments are presently available to increase survival in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy. We aimed to assess efficacy and safety of zalutumumab, a human IgG1 monoclonal antibody targeting the epidermal growth factor receptor, for overall survival in such patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
333-43
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21377930-Adult,
pubmed-meshheading:21377930-Aged,
pubmed-meshheading:21377930-Aged, 80 and over,
pubmed-meshheading:21377930-Antibodies, Monoclonal,
pubmed-meshheading:21377930-Carcinoma,
pubmed-meshheading:21377930-Carcinoma, Squamous Cell,
pubmed-meshheading:21377930-Disease-Free Survival,
pubmed-meshheading:21377930-Female,
pubmed-meshheading:21377930-Head and Neck Neoplasms,
pubmed-meshheading:21377930-Humans,
pubmed-meshheading:21377930-Male,
pubmed-meshheading:21377930-Middle Aged,
pubmed-meshheading:21377930-Neoplasm Metastasis,
pubmed-meshheading:21377930-Neoplasm Recurrence, Local,
pubmed-meshheading:21377930-Neoplasms, Squamous Cell,
pubmed-meshheading:21377930-Organoplatinum Compounds,
pubmed-meshheading:21377930-Receptor, Epidermal Growth Factor,
pubmed-meshheading:21377930-Salvage Therapy,
pubmed-meshheading:21377930-Treatment Failure
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.
|
|
pubmed:affiliation |
Cliniques Universitaires Saint Luc, Brussels, Belgium. jean-pascal.machiels@uclouvain.be
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
